Driving Performance at Scale: The agilon Framework Technology-Enabled Clinical & Quality Programs - AGILON HEALTH INC
Hello, everyone. Thank you for joining us and welcome to the Driving Performance at Scale, the Agilon Framework Technology-enabled clinical and quality programs presentation. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialed in to today's call, please press star 9 to raise your hand and star 6 to unmute. I will now hand the conference over to Evan Smith, Senior Vice President, Investor Relations. Evan, please go ahead. Good afternoon. My name is Evan Smith and I am Senior Vice president of Investor Relations. I would like to welcome everyone to Agilon Health's Clinical and Quality Investor Invent, Driving Performance at Scale, the Agilon Framework. Thank you for joining us. Turning to slide two, and before we begin, I would like to remind you that our remarks and responses today may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-thinking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings, including our most recent Form 10-K and Form 10Q. Forward-looking statements speak only as of today, and we undertake no obligation to update them. I'd also like to note that the clinical quality and utilization metrics shared today are agile and calculated unless otherwise noted, and some reflect observational comparisons rather than causal results. Source notes accompany the slides. Turning to slide three. Today, you'll get a closer look at the clinical and quality engine behind our total care model. You will hear how our technology platform turns data into insights at the point of care, how our clinical pathways for heart failure, serious illness care, and dementia are improving both care and outcomes, as well as how physician engagement and our quality programs bring it all together. With me today are Dr. Karthik Rao, our Chief Medical Officer, Varun Anand, our Interim Chief Technology Officer, Heidi Hittner, our chief business operations officer, and we're especially pleased to be joined by Dr. John Copeland of United Physicians, one of our leading physician partners. As you can see from the agenda on slide four, Dr. Rao will provide a deep dive into our clinical framework and pathways. Varun will provide an overview of our tech platform and examples of of our technology and AI initiatives in action. Dr. Copeland will walk through how all of this works in the real world at the point of care, and Heidi and Dr.Copeland will provide insight into our continued execution and the value creation from our quality programs. Following the presentation, we'll open the lines up for Q&A. With that, I'll turn it over to Dr. Karthik Rao. Karthick. Thanks Evan. Turning to slide six, Ashlawn is transforming healthcare for seniors empowering primary care physicians to deliver proactive care focused on the entire health of their patients we serve as a long-term partner to local physician groups and health systems entering into 20-year partnerships that honor physicians independence and support improved outcomes and experiences for physicians and patients we partner with approximately 2 200 primary care physicians caring for roughly 500 000 medicare patients and we manage approximately 6 billion and total medical expense our scale gives us a growing data asset proven playbooks and ai supported insights and tools we can deploy in real time with each partner and business line our proximity to the physician enables us to embed the support directly into their workflows creating a more effective model to enhance access and care and advance a system built on the value of care On slide 7, Agilon's total care model brings four capabilities together, centered around the primary care physician, and focused on delivering better outcomes for patients. First, our partnership builds on the relationship between local physicians and their patients. We recognize that the trust between a primary care position and patient is perhaps the most important asset in healthcare. Our work focuses on helping physicians preserve and strengthen that relationship. Furthermore, the partnership economics are shared. We share our value creation with physician partners and reinvest in the community, which aligns incentives over the long term. Second, the network connects physician groups so they can share best practices, bring proven approaches into their communities, and also create an ecosystem for innovation to trial in new programs and tools. You've seen the success of this knowledge sharing through our clinical and quality programming. Third, the care model is centered on earlier evidence-based intervention, coordinated care, and better management of chronic conditions, as we will discuss today. Fourth, enablement capabilities form the foundation of our intelligence layer, including integrated data, analytics, and AI. Because these capabilities give physicians actionable insights within their workflow and support our market operations, they are critical components to getting patients the right care at the right time. Together, these tools are designed to help physicians keep patients healthier, prevent avoidable hospital visits, and manage the total cost of care, while keeping clinical decisions grounded in the local physician-patient relationship. Turning to slide 8, we'll discuss the problem we are solving. Over the last 20 years or so, physicians have seen rapidly rising practice costs that have outpaced Medicare reimbursement, resulting in a 33 decline in real medicare payments this environment has pushed physicians to see more patients to offset declining reimbursement making it harder to deliver the quality of care they want to provide this structural challenge is in part contributing to the rising national primary care shortage that you see illustrated here taken together these trends point to a significant challenge for a health care system a strong body of evidence shows that greater primary care physician density is associated with longer life expectancy, and that primary care is the only medical specialty shown to reduce unnecessary hospitalizations while likely lowering overall healthcare costs. The implications are clear. Primary care is a foundation of a high-performing healthcare system. Without meaningful reform to primary care compensation, improvements to the PCP experience, and greater support for physicians in delivering exceptional patient care, the very foundation of a healthcare system risks being weakened. In parallel to this challenge, on the patient side, we see the majority of Medicare spend on chronic and mental health conditions. This spend is concentrated in patients with a multitude of chronic conditions with over 70% of the Medicare population having four plus comorbidities that account for over $800 billion of spend in the system. Solving this requires a payment model that aligns incentives with proactive care designed to keep patients well by providing the appropriate care for chronic conditions earlier to prevent condition progression and ultimately improve quality of care and reduce unnecessary utilization. Turning to slide nine, let's double click into how we solve that problem by ensuring we focus resources on our sickest patients and enable a proactive system of care by bringing together different components of the platform to deliver better outcomes. It starts on the left with our burden of illness program, which is centered on understanding each patient's health status through both their existing conditions, new conditions that a patient may develop over time, and proactively identifying key conditions while we can still mitigate progression of disease. This ultimately enables risk stratification of our patients so we can appropriately match care intensity with patient need, from prevention for relatively healthy seniors to more comprehensive and in-home support for the highest risk patients. It's important to note that within the Agilon population, the top 15% or so accounts for 40 to 50% of our overall spend. We believe we can have an outsized impact on the quality of care the subset of patients receives and avoid unnecessary exacerbations of disease, which lead to avoidable utilization. For serious illness patients or those approaching the end of life, we focus on compassionate and goal-concordant care through coordinated advanced care planning, palliative care and hospice. For high risk patients who may be homebound and often have five plus chronic conditions, we focus on prioritized primary care access, home care teams and focused high risk patient clinics. You've heard about our focus on clinical pathways designed to treat high prevalence conditions end to end and our focus the fundamentals of value such as our high performing quality program. We will discuss both of these in more depth today. Underpinning this approach is a technology platform that leverages significant operational and patient-specific clinical data that puts actionable insights into the workflow of both our PCPs and our market teams who are working each day with our primary care physicians to enable this care model through education, operations support, and expanded network capabilities and tools. our engagement approach and technology platform serve the ultimate goal of operationalizing our care model by surfacing timely insights to pcps and market teams that ultimately drive actions designed to deliver the right care at the right time and place over the portion of the discussion today we'll dive deeper into different components of our clinical model and key enablers starting with our technology platform followed by clinical pathways physician engagement and our quality program. To start, I'll hand off to Varun to dive deeper into our technology and data platform. Thanks, Karthik. Turning to slide 11, our technology and data platform is the foundation of how we enable our partners to drive improved outcomes for their patients. Just to set the context of scale here and reinforce what Karthick previously mentioned, we're working in a multi-practice, multi-state, and multi-payer environment. means we're bringing together data from varying sources and formats. Let's first discuss about how it's built. It all starts with a rich data ecosystem where we consolidate various components of information about our members from different sources to create a longitudinal 360 degree view of what is happening with their health. At the core of it is our financial data pipeline which brings together membership claims and census information from our contracted payers to identify who our members are and their health journey. The PAIR data that feeds this is usually lagged by 30 to 60 days, which makes it a retrospective view of outcomes that we're driving. Our proximity to our providers allows us to add a near real-time dimension with our operational and clinical data pipelines. We get near real time data of events such as hospital admissions involving our patients through connections with our partner EMRs, health information exchanges, scheduling billing data, and administrative data. This view creates our operational and clinical data platform and gives us a more detailed view about what's happening on the ground with our members. The combination of each data set gives us the complete view of our members across timescales. As an example, claims in billing data may tell us that a patient had an echocardiogram test, but clinical data gives us the actual result of the test, adding more detail to the event. This data foundation feeds our intelligence layer, where we're combining humans and technology to create insights. We've invested heavily in this layer, leveraging our human expertise to build AI workflows to get deeper insights at the patient, population, and PCP level. We'll walk through some additional examples of this intelligence layer in the upcoming slides. All of our investments in the data and intelligence layers come to fruition only if they're delivered effectively within the workflow where care is delivered. This is why we've built out and integrated with a variety of end user technology tools that enable our physicians to access these insights at the point of care delivered right inside their EMRs. As we introduce more intelligence through clinical pathways and programs, we give physicians relevant patient context within the EMR so that they can make informed decisions while caring for high acuity patients. We deliver the same insights to our partner teams so that we can prioritize scheduling based on clinical need and analyze clinical performance across physicians and patient panels. They can coordinate transitions of care after a patient is discharged from the hospital as well as other interventions to impact overall cost of care and patient outcomes. These insights also support Agilon's operational teams, enabling us to centralize operations around validating appropriateness of diagnoses, financial planning, peer engagement and performance management. Our close relationship with our physician partners enables us to deliver and create value from these insights that are synthesized from our expansive data platform. Over to slide 12. To add some further context on how this works, we'll dive deeper into how this manifests while taking care of high risk patients. It all starts with our data ingestion, where we are combining financial data from our payers to real-time practice and clinical data from the primary care setting in their EMRs, acute and post-acute data from health information exchanges and real-time event notifications from ADT networks. Since our inception, our platform has accumulated more than 200 million clinical documents, 700 million lab results, 150 million claims connected across more than 65 pairs and 120 EMR instances. This data comes in different formats across different timescales, and a big part of our IP has been around aggregating it to create a comprehensive view of each member. This allows us to see a member's longitudinal history and identify insights and gaps that can help our physicians adjust care to drive the best outcomes. As an example, we may be able to identify potentially undiagnosed conditions based on this extended view of the patient. We could identify care gaps based on their existing conditions, or even identify candidates for proactive screening or gaps in treatment compared to evidence-backed clinical guidelines. As I said previously, these insights are all recommendations that are delivered directly into the PCP's workflow at the point of care. Physicians are able to independently evaluate these recommendations and act based on their clinical judgment. The outcomes we're driving here enable our physicians to deliver better outcomes for their patients through earlier and more proactive screening, improved treatment adherence, preemptive interventions to reduce avoidable hospital inpatient and ER visits, and overall improve the patient experience. These insights are generated increasingly through technology, fine-tuned through human-in-the-loop feedback mechanisms. We track the actionability and appropriateness of these insights very, very closely. And each physician evaluation feeds back into our insight layer to further improve these models. Turning to slide 13, to show you a few examples, we've pulled together illustrative views of what these insights look like within our system. The first one on the top left is how we're presenting insights at the point of care. As I talked about in the last couple of slides, we generate insights highlighting gaps in care, known conditions that have not been reassessed, previously undiagnosed conditions for which we have found clinical evidence or screening needs for a patient. These are all presented within the physician's EMR. Each one of these recommendations comes with a detailed memo that gives the physician context on why we're making that recommendation. Over the past year, we have built a GenAI clinical insight engine that goes through a patient's longitudinal patient record, evaluates them against our clinical guidelines, and evidence-based clinical literature to generate these recommendations. We also track physician responses on whether they agree or disagree with these recommendations, which in turn creates a feedback loop, improving the engine. There are also some workflows that require both the PCP and the operators at the practice or at Agilon to drive outcomes. The one on the top right is an example of how we're deploying workflow tools to enable operators to look at patients identified for critical screenings. Our intelligence layer is building a real-time patient cohort that looks at the longitudinal patient record to identify patients that are eligible for proactive screening based on clinical guidelines. Market operators and PCPs can then view these patients in both workflow tools and within their EMR to be able to take action. Once screened and diagnosed, the tools also track adherence to clinical protocols for these patients. As an example, we are tracking patients with a particular chronic condition and seeing whether they are on goal-directed medical therapy. Another great example of bringing our insights into physicians' offices is our prioritized scheduling tool seen on the bottom left. We leverage everything we know about the patient, their current unassessed disease risk, screening flags, high-risk identification, recency of their last PCP visit, and other acute factors like recent discharges to create a composite indicator of the clinical need of that patient. Our prioritized scheduling tool then surfaces patients with the highest clinical needs so that our operators can prioritize scheduling their PCP visits, ensuring that patients that need to be seen more frequently are added to the physician schedules. Last but not the least, another example is how we're surfacing time-sensitive transitions of care, such as a patient's move from a hospital to home and back to care teams in physicians' offices, as shown on the bottom right of the slide. This is a particularly vulnerable time for patients. We get real-time hospital discharge information along with the acute care records and leverage that data to identify patients that need to be seen by their BCPs within seven days of discharge. This timely follow-up gives the care teams an opportunity to clarify medication changes, address questions, and identify potential complications before they lead to another hospital stay. This helps patients get the continuous care that they need to bounce back. And back to you, Karthik. Turning to slide 15, and over the next few slides, we'll dive deeper into a specific area of our care model, clinical pathways, to show you how we design them, how our technology platform enables them, and how those insights get actioned to improve the clinical outcome for a patient. The goal of our clinical pathways is to create an end-to-end approach and repeatable framework across chronic conditions that have a disproportionate impact on the health and wellness of seniors. First, as Rune touched on, we start by identifying patients at elevated risk for a condition. Second, our PCP partners complete appropriate testing to confirm or rule out disease. Third, the PCP initiates and optimizes evidence-based treatment with additional support as needed. For example, a virtual dementia clinic to help with a cognitive evaluation and patient-specific treatment plan. Fourth, through the long-standing relationships our physicians have with their patients, we're able to follow patients over time, coordinating specialty care and matching support to their needs as the disease progresses. Finally, we measure what matters most across our operational process and clinical outcomes as a result of this care process, making sure patients get the appropriate treatment, improved patient experience, and fewer avoidable emergency visits and hospitalizations and and readmissions. Because this core framework is standardized, every new pathway can leverage the same technology platform and infrastructure while tailoring the requirements for each medical condition and PCP practice. This enables us to scale efficiently while addressing the specific needs of each PCP practice and high-risk condition. On slide 16, you'll find that at each part of the framework, we align clinical standards, embedded technology, and specific actions for the PCP and care team, so everyone is able to seamlessly work together to improve care. Let me illustrate the diagnose step to show you how these different components come together. A patient at risk for dementia will be flagged for a primary care physician at point of care to complete a screening test, such as the Montreal Cognitive Assessment, which is a validated test that has been defined as part of the pathway through our clinical solutions team. Assuming the initial screening test is positive, we have set up virtual dementia clinic offerings with care standards defined by our clinical solutions team in various markets to expedite access to a dementia care specialist for a full cognitive evaluation for definitive diagnosis and then smooth transition into treatment and care management, once again with stringent care standards requirements. At each step in the process, our technology integration will ensure the PCP receives updates and care via their native workflow in the EMR. Historically, patients like this may go undiagnosed until their disease has significantly progressed. This is particularly relevant in dementia, where subtle changes in memory or cognition may initially be attributed to normal aging. When screening and follow-up vary, these early warning signs can be missed. We're working to make these processes more consistent and across conditions so patients can be diagnosed and receive appropriate care sooner. I also want to point out that we measure outcomes, both process and clinical, continuously through performance dashboards and variation reviews so we can identify gaps in real time and improve our processes week over week. Next, we'll use our clinical pathways framework to dive deeper into heart failure on slide 17. Let's start with the clinical problem are solving for patients. Heart failure is the leading cause of preventable hospitalization among Medicare patients, costs approximately $30,000 per patient annually, and carries a national 30-day readmission rate of about 20%. In addition to that, there's been a 40% increase in age-adjusted heart failure mortality over the last 15 years, one of the few conditions where we are going backwards as a country on helping people live better. We would all look at that and say that's not the care we'd want for ourselves or family members we can do better as i mentioned rei tools help identify high-risk chf patients earlier which is followed by evidence-based screening protocols potential confirmatory diagnosis and intervention leveraging guideline directed medical therapy ultimately putting the patient on a better care plan and addressing disease progression to improve outcomes and reduce unnecessary utilization our pathway includes structured follow-up utilization of virtual or in-person pharmacy in many markets and co-management with cardiology both aimed at directly improving our patients health turning to slide 18 we can ask what does this look like you can see in the diagram how we move diagnosis from time of inpatient admission to outpatient by early detection through evidence-based screening in the clinic. If diagnosed, we know GDMT treatment is a current gap, so we support PCPs with virtual pharmacy or in-market pharmacy solutions. Through more frequent follow-up, including virtual check-ins between office visits, pharmacists work alongside physicians to monitor symptoms and side effects and help adjust medication doses. They also help patients navigate payment assistance programs for expensive medications. This helps patients get on the right therapy and stay on it. Lastly, many heart failure patients will progress, and unfortunately a limited number benefit from palliative and hospice care if symptoms do escalate. In a non-agilent scenario, many of these patients ultimately crash into hospice with less than 14-day stays, which we know creates a suboptimal experience for patients. We're able to flag these patients much earlier in their disease trajectory decline using our risk stratification tools and engage these patients in advanced care planning conversations and palliative and hospice care when appropriate which leads to care that is more goal concordant overall this is shifting heart failure care from a reactive symptom-based approach to one that is proactive and more patient centered which improves the quality of care delivered patient outcomes and reduces unnecessary medical cost let me bring this to life through a patient example and then share results at a network level on slide 19. at 67 rick a retired emt was struggling to manage his own health he was living with shortness of breath and frequently visiting the ed for care his ex-wife helped manage his medications and pay for them without that support financial strain and depression made it harder for rick to stay on track our risk algorithms flagged Rick as a candidate for the high-risk clinic in the market, where he would benefit from up to one-hour visits with the team, monthly touch points, and multidisciplinary support, including a pharmacist as part of the heart failure pathway. The best way for everyone to understand the value we're delivering is to directly hear from Rick on his experience. I was just down about my health thinking nobody could do anything because I had been sick for so long and I came up here and really wasn't expecting that much but it didn't take but two three trips when they started looking at my medicines telling me to stop doing this and start doing this telling me how to live happy and telling me how to leave healthy and I started having a mental attitude about you know I matter again so through our partnership with Agilon we have extra assistance in determining the level of illness of our patients Rick is a great example of a patient who is a prime candidate for our value-based care high-risk Medicare clinic because he has multiple medical problems that aren't well controlled and it was very difficult to identify the root cause of the inability to control his medical problems until we approached it from a multidisciplinary team-based approach. I can walk better or when I say better I can walk a further distance without having trouble breathing. I don't wake up of the headache because my blood pressure is sky high. My sugar don't go out of control like it used to. And it's just, when I wake up in the morning, I feel like getting up and feel like living, you know. The care I've received here has kept me out of the hospital a lot more than I did because I was going in two or three times a month, you know and now it's it's very rare so that's hit me a great deal staying out of the hospital my birthday was a couple weeks ago and I don't have a lot of family living and so I came up here and they seen it was my birthday and when I left they all gathered around and that signed a birthday card and give it to me which I thought was real touching it's about the only gift I got that day but I've still got it. It's still home and little things like that's what matters. I don't think they realize exactly how much they help or have helped me in my situation. You know, I'm not just another patient to them. I really believe that. I'm a person first and a patient second. You know, and they just need to realize how much they do for me and I'm sure they do it for everybody but gosh saying thank you is not enough. I mean how can you thank somebody for turning your life around from being miserable to having a new outlook on life. As you just heard the focus support of a great team with the right access and a high-risk clinic combined with the standards and tools established through our clinical pathways helped turn Rick's story to one of unnecessary suffering to waking up with joy and purpose. Over the first six months of his enrollment, Rick's emergency room visits, many of which were heart failure related, fell from 14 to 7, a 50% reduction with anticipated continued improvement. As his conditions became better controlled, his depression symptoms also improved. He regained independence and confidence in managing his health. He returned to oil painting, a longtime passion he had set aside as his health declined. His story shows what becomes possible when we align payment systems with keeping patients well and provide care teams the tools, resources, and access to support our sickest patients. Turning to slide 20, as evidenced by what you heard with Rick, this pathway is working for many patients. Only 5% of our heart failure diagnoses occur in the acute setting, such as a hospital, compared with a national benchmark of about 40%. For heart failure patients engaged with our virtual pharmacy solution, adherence to optimal guideline-directed medical therapy is about 50%, compared with the benchmark of 20%. And we know patients receiving optimal therapy reduce admissions. Depending on the type of heart failure and the therapies used, guideline-directed therapy reduces heart failure hospitalizations by 20 to 40 percent. Also important is that patients agree they are receiving comprehensive, high-quality care. Turning to slide 21, I want to touch on a couple additional pathways. First is serious illness care, which is focused on a better care experience for patients approaching the end of life, one of the most challenging periods of care to navigate for a senior in their family. Why are we focused here? 71% of Americans say they would prefer to pass away at home, yet only 31% do. Furthermore, we know that more intensive care in this period of life is often perceived as unnecessary suffering from caregivers. We know that getting the right patients to hospice at the right time improves both these measures. And only 53% of seniors benefit from this service, another area we would look at and say we have to be better. Our Serious Illness Care Pathway helps physicians have challenging and oftentimes sensitive goals of care conversations earlier, giving patients and families time to understand their options and plan care that reflects the patient's wishes. Dedicated clinical reviewers identify patients who may benefit from palliative and hospice care, supporting PCPs in deciding when and how to engage. A peer-reviewed study conducted early in Agilent's palliative program found that patients in the pathway, particularly those receiving palliature care, spent more than five additional days at home in the last six months of life, and 17% fewer passed away in a hospital or ICU. Fewer avoidable admissions also contributed to approximately $10,000 in lower end-of-life healthcare costs for those enrolled in the pathway. pathway. Most importantly, those additional days mean more time at home with loved ones. Turning to slide 22, we demonstrate another pathway where we see a significant opportunity is dementia. Dementia was associated with an estimated $105.9 billion in Medicare costs in 2025, and about 10% of adults 65 and older are estimated to be living with it. Yet an An estimated 60% of dementia cases in the U.S. go undetected. Families carry much of this burden. Our dementia pathway follows the same framework as we've outlined with other care pathways, starting with earlier identification. Given the sensitivity around this topic, each practice applies Ashland's dementia-specific tools in a way that is aligned with their patient needs. Depending on the practice, that may mean systematic cognitive screening for all patients 65 and older, or prioritizing older patients, since risk rises with each decade of life. RAI tools add another layer of identification, recognizing clinical patterns that suggest a patient may benefit from further cognitive evaluation. Diagnosing dementia is more complex than diagnosing heart failure. It requires evaluating both cognitive impairment and functional decline, which takes specific training. In some practices, the PCP conducts a full evaluation. Others train a subject matter expert or refer patients to a specialist evaluation through a telemedicine partner. Most important, though, is that however the evaluation happens, every diagnosed patient receives an individualized care plan reviewed by their own PCP. After diagnosis, the focus shifts to high-quality ongoing care for both the patient and their caregiver. Here, we follow the care ecosystem model. At the center is a care navigator who builds a relationship with the caregiver and patient. This care navigators becomes a trusted resource with touch points about monthly. The navigator is backed by a multidisciplinary team, including clinicians who support medication management and dementia-specific questions and behavioral health specialists. Protocols cover medication reconciliation, safety screening, caregiver well-being, and goals of care, plus behavioral management guidance for patients with more advanced diseases. For a family, this means a diagnosis that comes early enough to plan and a trusted person to call when something changes, rather than a crisis that ends in the emergency room. That's the kind of care we would want for our own parents. On slide 23, you see our results validate the success of our clinical programs and support our commitment to expanding existing and new pathways going forward. Compared with Medicare fee-for-service benchmarks, our Medicare Advantage patients have 10% fewer hospital admissions per thousand, 24% fewer readmissions, and 8% lower emergency room utilization. Just as important is how our members feel about the programs and level of care they are receiving. And based on a net promoter score of 87, I believe we're doing a great job turning to slide 24 i want to discuss the significant opportunity ahead of us to improve care and lower cost through the advancement of existing clinical pathway programs and launching new ones to address several high-risk conditions we discussed the heart failure pathway in depth today which we will continue to enhance alongside serious illness care our transitions of care planning as well as high- risk patient management in the future we look to address other high-cost high-needs conditions, including new pathways in oncology, musculoskeletal care, and other cardiac conditions, while continuing to scale lung health and dementia pathways across all markets. You will see us balance time to value, complexity, patient impact, and cost as we assess the roadmap for each pathway. The key takeaway again, which is illustrated here, is that there is significant value creation opportunity over the next few years as we focus on high-risk and high-cost conditions to improve patient care and outcomes and reduce unnecessary medical cost. Now, I'll turn over to Dr. Copeland to discuss how our physicians engage with the Agilent model in depth. Thank you so much, Karthik. Turning to slide 26, I'd like to build on what Karthick just shared and show you what this looks like from the perspective of a practicing primary care physician. Here at United Physicians in Southeast Michigan, we began our partnership with Agilent in 2022 because we wanted to do more for our patients, particularly those with complex medical needs or at greater risk of declining health. As primary care physicians, we know that a patient's health can change very quickly. Those changes aren't always obvious, especially when patients see multiple specialists or attribute new symptoms simply to aging. Our partnership with Agilon provides additional information, technology, and clinical support to help us recognize those changes earlier and respond before patients potentially end up in the emergency room or hospital. This pyramid illustrates how we match care to each patient's clinical needs. At the bottom are relatively healthy patients, where we focus on prevention and chronic disease management. As risk increases, we look for new symptoms, changes in function, or increased healthcare utilization that might prompt earlier intervention. For those patients with more complex needs, coordination across specialists and care settings becomes increasingly important. And for those facing serious illness, early conversations help us understand their wishes and guide treatment decisions before a crisis occurs. Ultimately, our goal is to understand where patients are in their clinical journey, recognize when their trajectory is changing, and provide the right care at the right time. Now, on slide 27, how do we turn that information into meaningful clinical action? Our primary care physicians meet regularly with their care teams to review patients with higher risk or more complex medical needs. We look at what's happening with each patient, how their health may be changing, and where additional treatment or support might be helpful. As Varun demonstrated earlier, Agilon's technology helps bring together the clinical information and resources that support these decisions. But the technology doesn't replace physician judgment, it supports it. That's especially important for older adults with multiple chronic conditions, where treating one condition can sometimes complicate another. From there, we then develop an individualized 90-day action plan. That may include more frequent visits, medication adjustments, specialist coordination, care management, behavioral health, or caregiver support. For patients with advanced illness, it may also include conversations about goals of care, palliative care, or hospice care when appropriate. We then reassess patients regularly, reviewing hospitalizations, follow-up appointments, medication optimization, and other important care needs. When appropriate criteria are met, patients can transition out of intensive management while continuing longitudinal primary care. The value of this process is that it gives our physicians and care teams a consistent way to identify patients who need attention, develop a plan, and follow through. It also helps build and reinforce the clinical muscle we've all been trained to provide at the point of care. Turning to slide 28, I want to bring this down to the individual patient level because ultimately that's where value-based care begins. This is an adapted example of how we organize and track our patients who are reviewed, including clinical status, medications, care needs, and individualized action plans. Let me draw your attention to the second row here. This is an 82-year-old female patient with stage D heart failure who is tolerating two of the four pillars of guideline-directed medical therapy. As physicians, we recognize the importance of evidence-based treatment, but also that patients with advanced heart failure may not tolerate every recommended medication. Our responsibility to her is to consider her symptoms, functional status, trajectory, and goals of care while developing the appropriate treatment plan. And with stage D heart failure, that may also mean recognizing when she's approaching end of life and discussing both palliative care and hospice needs, ensuring that she and her family understand all the options available to them. As Varun highlighted earlier, technology can help organize and bring together relevant clinical information, but it's the physician and care teams who translate that information into individualized clinical decisions. We're not simply treating a diagnosis or checking a box, we're treating an individual patient. Each review leads to a specific action plan, including treatment decisions, follow-up, and caregiver support. We reassess at least every three months and adjust the plan as the patient's needs change. For me, the real value is the opportunity to provide more proactive and personalized care. We know that for older adults, hospitalization can sometimes lead to lasting loss of strength or independence. As physicians, we want our patients to remain healthy enough to do what matters most to them with care that reflects their individual wishes and goals. And I believe this proactive approach isn't simply what physicians aspire to provide. It's the kind of care that our patients deserve. Care that's personalized, anticipates their needs proactively, and doesn't wait for a crisis before we act. That's what value-based care means to me, having the support to practice more proactively and provide the kind of care I would want for someone in my own family. And with that, I'll turn it over to Heidi on slide 29 to discuss how our quality programs support this same commitment to our patients. Thank you, Dr. Copeland. As we move to the next slide, you just heard from Dr. copeland how physicians engaged in our model are providing the kind of care we would all want for our own parents. I now want to thread the needle on how these programs and other initiatives impact quality as defined by CMS for every patient at every visit. Whether that patient is inside the four walls of the PCP's office or we're supporting closing gaps in care through screenings or medication support, every opportunity is a key component to our success. Our integrated workflows reduce the administrative burden on the physician and their care team to ensure that that information on quality care makes its way to the payer. CMS designed quality, which includes access to care and patient satisfaction, to be a meaningful part of both Medicare Advantage and ACO models. Payers tell us that they value our strong performance and quality and our ability to help partners improve their quality performance. Both MA payers and CMS directly through the ACO model provide quality incentives to reward high levels of performance due to the value it creates for the patient and the overall health care system. Blood pressure control is one of those triple weighted quality measures. I'll turn it back to Dr. Copeland to explain why it matters so much for patients on slide 31. Thank you, Heidi. On this slide, I'd like to focus on one of the most common conditions we manage in primary care, hypertension, and why consistent longitudinal care really matters. Earlier, Karthik and Varun described Agilon's clinical approach and the technology capabilities that support it. is a practical example of why those capabilities matter. We talk about blood pressure so often that it's easy to overlook its importance. Yet more than 120 million American adults have hypertension and most don't have it adequately controlled. The consequences to this are significant. People with high blood pressure are approximately four times more likely to die from stroke and three times more likely to die from heart disease. But bringing blood pressure under control can reduce the risk of cardiovascular death by roughly a third. That's an enormous opportunity to address one of the leading causes of illness and death in this country. It's why we check blood pressure at nearly every office visit. That simple measurement can reveal a serious cardiovascular risk a patient may not even feel. But identifying hypertension is only the beginning. The real work is consistent follow-up, appropriate medication adjustments, addressing adherence, and maintaining blood pressure control over time. It's also why blood pressure is such an important quality measure for physicians and health plans. No single office visit defines good hypertension management. It's the ongoing treatment and follow up that helps reduce a patient's risk. And that's another example of proactive primary care, recognizing an opportunity to intervene and consistently following through. Hypertension is just one example of many of how proactive management can help address important clinical risks. And now on to slide 32, I'll turn it back to Heidi to discuss how we apply this approach across broader quality programs. Thanks, Dr. Copeland. At Agilent, we have a quality playbook with specific actionable priorities in four areas. Chronic condition management, such as hypertension, reducing unnecessary hospital admissions, preventive screenings, and patient experience. And we work with each partner to identify their areas of opportunity and how to improve. We share best practices across the network to improve quickly, such as creating workflows that message the PCP and their care team in their EMR two to three days before the next PCP visit for diabetic patients who may have an open statin medication gap and provide information from pharmacists on suggested options to be able to address that potential care gap. We also work relentlessly with payers and their quality resources to ensure we are closing all possible care gaps appropriately. An example around blood pressure is ensuring that blood pressure values are in a format to reach the payer, that the payer is taking advantage of all the ways they could receive blood pressure data, and to monitor patients where that blood pressure gap was previously closed and it reopens with another provider visit. The importance of of that longitudinal primary care. Patient experience matters, and we're proud of our partner's world-class patient satisfaction. After every PCP visit, we survey patients about their experience. We've surveyed over 200,000 patients across our network so far in 2026, and each month physicians receive their own patient feedback along with improvement ideas. Moving to slide 33, We wanted to show the impact these initiatives have had across our medicare advantage data for two years 2024 and 2025. and see the impact on closing gaps to reduce the patient's time spent in the hospital hospital admissions and readmissions are both measured in inpatient or readmit per thousand. Dr. Copeland talked about why blood pressure control is so important to manage. The left side of the page is patients who have high blood pressure and the right side of the pages are patients with diabetes. Among our Medicare Advantage patients, those with controlled blood pressure for both years had 16% fewer admissions and half the readmissions as those who had uncontrolled blood pressure for both year. Among our diabetic Medicare Advantage patients over those same two years, those with controlled A1C or blood sugar control had 38% fewer admissions and nearly a third fewer readmissions. Turning to the next slide. Our emphasis on these programs and providing excellent quality to our patients results in better than average Medicare Advvantage performance on many key star measures, which is hard to do, especially as we've added new partners, patients, and individual PCPs to the platform. CMS established star ratings to monitor and to reward ongoing improvements in quality of care, and they rate plans from one to five stars. Five star is the highest, and it's based on a standard set of measures. CMS selected those measures for their impact in improving quality outcomes. Simply put, better care means a higher star rating. Each of those measures is determined by how many patients who meet that defined measure criteria have had that gap in care successfully closed. Every year in October, CMS calculates the results from all the health plans, and they assign star cut points based on the nation's performance on each measure. Those thresholds are raised over time to propel improvements. On the left you'll see all of our groups for measurement year 2025 on 13 quality measures and we've grouped those into categories including cancer screenings, chronic disease management and transitions of care. We're very proud to demonstrate four and five star level of performance across those areas. Transitions of care especially readmissions is harder to impact and as Dr. Rao talked about earlier we have spent much time this year identifying processes and areas that that we can improve our performance in 2026. Overall, we're very proud to have an average 4.2 consolidated star rating across all measures for our contracted health plans. On the right side of the page are those same 13 measures as a percentage of gaps closed over time. That line continues to trend up over time, we closed 3% more gaps in 2025 than 2024. That's across more communities, partner types, and systems that we're able to improve care across specific conditions. That quality of care is also supported across all seniors, MA and ACO. And we do that through our full risk models. We have an 83% annual wellness visit completion rate and a 93% assessment of chronic conditions. and 98% of those patients tell us that they receive comprehensive, high-quality care. And finally, moving to page 35, we have a model that's built to compound value for our patients and our partners. As more physicians join our network, we gain more data and sharpen our insights. That drives better outcomes, it strengthens our relationships, and it will attract more partners. That cycle is how we continue to deliver high-quality care, lower total cost of care, and durable value for our patients, physicians, payers, and shareholders. We will now open the floor to questions. Thank you. We'll now begin the question-and-answer session. Please limit yourself to one question and one follow-up. If you have further questions, please re-enter the If you would like to ask a question, please raise your hand now. If you have dialed into today's call, please press star 9 to raise your hand and star 6 to unmute. We ask that you pick up your handset when asking a question to allow for optimum sound quality. And if you are muted locally, please unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Jaylindra Singh from Truist. Your line is open. Please go ahead. Jaylinda Singh, Truist, Hey, can you guys hear me okay? Yes. Perfect. Thank you so much. A very, very helpful presentation. I really appreciate you guys doing this. My first question is for Dr. Rao. You know, I was curious, how consistent are these clinical and utilization results you share across Agilent's markets and physician partners? Can you discuss the, like, performance range between the top quartile of physicians and bottom quartiles? What is the variance there? Timothy Stenzelman, Ph.D.: Hey, Jalinder. Thanks for the question. Look, I'll start by saying some of that variability is a result of maturity of groups in our network. we do generally see is that over time, you do reduce that variability quite a bit. And I'll give you an example. When we think about our heart failure clinical pathway that we started roughly 24 months ago, you saw pretty significant variability both in screening and in treatment for that condition. Over the course of about a year and a half, we've reduced that pretty meaningfully across the network, and we continue to make progress, especially on the treatment side. And what you see is as you reduce that variability, that translates into outcomes and in heart failure in particular, such as site of diagnosis, moving from the inpatient to the outpatient side. And I think those things then translate to downstream inpatient utilization, ED utilization. And so without going into specific numbers market by market, I will say, yes, there is variability, but we see that reducing over time. And I think that the process that we've taken around pathways and focus interventions, we've seen pretty meaningful progress from. And that's helpful. And then a quick follow-up, this might be for Varun. I was curious if you could provide any more color around how the GenAI Clinical Insight Engine you talked about has improved performance compared to prior loose days or manual clinical review process you guys used to have. I don't know if you can share any data around like change in recommendation accuracy or maybe prediction acceptance, maybe clinical review time. Anything will be helpful to put things in perspective, the impact this engine is having on the overall ecosystem here. Sure, sure. Thanks, Jayendra. That's a great question. So we started working on the GenAI engine, I think, close to about 12 months ago. And as I mentioned, you know, a very key part of that is working very closely with our clinical teams to kind of identify the right logic to implement to identify these insights. But then more importantly, also be able to put it, you know, we have a fairly high bar in terms of accuracy and relevance before we actually put something in front of physicians. But we also have this feedback loop that continuously improves it, right? So I think with the Gen AI side, what we've generally seen is that as we've got more variability in data and we have more sources of data, it generally performs better to be able to capture signals in the clinical as well as bare data, right? And then in some cases also be clearer in terms of confidence scores of that suggestion as compared to like, you know, running, you knows, rule-based algorithms and so on and so forth. Over the last 12 months, of course, we've seen an increase in our ability to identify previously undiagnosed conditions. A lot of that is now showing up in our performance as well. But at the same time, as we fine-tune these, it's actually better experience for the physicians as well, because the recommendations that they get are actually more fine- tuned to what they'd expect to see, A. And B, it also has the relevant information in that memo or in that insight for them to be able to truly evaluate it without having to spend a lot of time, which was previously the case without Gen AI. Your next question comes from the line of Amir Farahani from Evercore. Your line is open, please go ahead. Hey guys, can you hear me? Yep, we can hear you. Yes. Hey, guys. Can you hear me? Okay, great. Thanks for taking my question. Great session. I guess looking back over the past few years, maybe if you could shed some light in terms of some of the biggest lessons you've learned in terms of Agilent model work as expected and was very successful in areas that you thought you needed more work and you're kind of working on right now. And maybe you can talk about a little bit how those lessons have changed your clinical priorities and the support you provide your physician partners. Thank you. Sure. And so, Meera, I'll start and I'll let others weigh in. I think, look, if you look back two to three years, I think a few key lessons that we've learned, and I will go into more detail in each of these. The first, I would say, is how we actually design and deploy end-to-end clinical solutions to drive towards an outcome. And two, I'd say how we better leverage our proximity to physicians to actually drive that change management through. And I would actually say three, too, on how we actually integrate technology into the point of care and workflow for our physicians. And so I'll double click into each of those. When I talk about designing end-to-end clinical solutions, when we look at our historical process, how we did this, we would generally only take part of a solution, such as if you think about serious illness care, we focused a lot on best-in-class care delivery. but I would say there was a big opportunity in the engagement side of that process that we probably needed to spend more time on. When we now roll out solutions as part of our end-to-end clinical pathways, it really takes a construct of thinking through everything from engaging the right members through treatment of those members and follow-up of those numbers, and I would also say the measurement of outcomes. And going through that process I think has allowed us to drive differential results, as you've seen through things like our heart failure pathway. The second part of this, too, when we talk about proximity to physicians, I do think it's a unique component of our model, and how this ends up showing up is how we go and drive change through our markets, and it happens in a few different ways, and we've become much more structured about this as we've grown and learned. One, when you think about it at the network level, we have network-wide leadership events a couple of times a year where we really align on the why behind why we do things. And that why centers around patient care and improved clinical outcomes. Those really become an opportunity to align around priorities with our broader network. Two, I'd say there is continuous engagement, especially with our physician and market leaders that we have at least monthly. we bring the network together virtually to really share learnings. And I think you've seen this through heart failure, you've seeing this through a serious illness pathway, new information comes to light, we optimize, we iterate, and that is a constant cycle. And we spread those learnings to our network. And a lot of that learning innovation happens from physicians like John, who are part of our leadership in those markets. And lastly, we are meeting with those physicians on a weekly basis in markets. And what's so important is that we can bring them data to help them understand variances to what's best in class and really help solve workflow issues, process issues, technology issues, but also really help them understanding the why and why that will help them take better care of patients. And so I would say those are two of the big things that I think are driving differentiated performance today and will as we go forward. And Vroon had a lot of the technology components of this, but I think a lot of that centers on figuring out how we get insights to the provider within their workflow to make the decision at the right time for that patient. Your next question comes from the line of George Hill from Deutsche Bank. Your line is open, please go ahead. Yeah, I appreciate you taking the question. This one's for Heidi. Heidi, which of these disease states in development should we think is being most important for bending the cost curve and reducing PMPM medical costs for Agilon and its provider partners? And should we take it as an additional cost curve? I mean, I think it's a good question. I think if today's presentation is additive to kind of prior cohort analysis that we've seen from the company, or is this like just the continuing progression that keeps us like in line with the cost reduction expectations we've seen from the company. Thanks. Thanks so much, George. You know, I appreciate there's a lot of overlap between traditional kind of quality measures and clinical pathways. And so I would, I'll highlight a couple of examples that we talked about to talk about what's consistent and kind of progress against that and what's new. So the first one, if you think about hypertension and cardiovascular disease, there are consistent MA quality measures that relate to those programs and measuring those. And we showed the benefit and the reduction in the admissions and readmissions from patients who were controlled there versus uncontrolled patients. Incrementally, as Dr. Rao talked about with our heart failure clinical pathway, you see that expansion in the end-to-end process of GDMT or guideline-directed medical therapy, and the incremental benefit you see in reducing hospitalizations for patients who are fully controlled on four-pillar GD&T. That's addition to a traditional kind of MA-STARS measure. Another example that we talked about that would be incremental was our serious illness pathway. And so as Dr. Copeland gave kind of that example, walking through the elements of identifying those patients, designing an end-to-end care pathway for those patients. There are certainly measures like readmissions or follow-up after a transition that are traditional quality measures that we manage, but there's incremental progress made from being able to identify those patients sooner and fully implement that care pathway. Our patient, Rick, that you heard from in the video was another good example of a very complex patient that had that wraparound capability. And you heard about the tremendous impact it had in reducing his number of inpatient stays. So there's a portion that are traditional quality measures and we're making good progress against it. And there is a component of each of those that really overlaps and provides incremental value in reducing overall cost. you know, you're always fighting other factors that are involved in medical cost trends. So unit cost is a piece that you're also combating against that, but those are key elements to impact the utilization piece. Thank you. Your next question comes from the line of Matthew Shea from Needham. Your line is open. Please go ahead hey guys thanks for taking the question and appreciate you guys putting on this event super helpful um wanted to try and better understand who bears the drug cost in us the chf program so slide 20 got about 50 of virtual pharmacy patients on all four of the heart failure drug classes and several of those are expensive branded therapies and at the same time you know your part d exposure has fallen to about 15 maybe going lower so it seems like payers are increasingly carrying that drug spend while you capture the avoided hospital costs. Just curious, has that come up in contracts or payer conversations at all? Do they want to share in those medical savings in return, or how does everyone get made whole as a result of those savings? I'll start by saying I think we're pretty aligned with the payers when we talk about making sure patients receive evidence-based therapy, and so that's been our focus with payers. And in conversations we've had, they've been very supportive of trying to get patients on the right medications. And so pretty aligned around that. You're right on our Part D risk coverage. For us, yes, that will show up and reduce utilization, but they're benefiting from that too through how we contract with them. So I do still think it aligns us pretty well. I think the other thing that we've seen on guideline-directed therapy is there are generics actually available for almost all of those pillars. So the net cost of GDMT is also coming down, whether directly or through options like the Mark Cuban Pharmacy that I know many of our groups leverage, which I think keeps those costs pretty manageable. Okay, that's a helpful clarification. And then if I could sneak in one more, Heidi, you mentioned readmissions, hard to improve, but you've identified areas or initiatives that could be helpful. Maybe just double click on that what do some of those initiatives look like and how long do you believe it will take to kind of see an impact from some of them yeah thanks so much matthew um a couple of areas that we talked about in the presentation that i'll refer to so heart failure was one of the first ones that we've talked about and so the opportunity to be able to manage patients better to keep them from getting in the hospital in the first place certainly has that downstream impact on readmissions um serious illness so similar to our patient rick that we showed the video of and dr copeland talked about in his workflow so these are all things that we have identified and taken actions in 2026 and many of these started kind of end of 25 to be able to put into place so these were all things have taken action and then as varun highlighted in our technology section and how our technology underpins and provides the information against all of that. We have also continued to make progress around making information about patients who are in the hospital easier to access for our frontline PCPs and their care teams and capabilities to wrap around those. So those are kind of three different areas, the cross-heart failure, serious illness, and then underlying our overall technology platform to make that easier to identify patients who are in the hospital. Certainly, we want to keep them out of the hospital to start with, so we have less readmissions to deal with, but a number of items that we measure operational progress against that we are pleased to see we are making progress against those in-year. You know, the one other additional piece of color I'd add is if you look in any of our markets, there's actually a relatively small number of patients that drive most of the readmissions. And so to Heidi's point, you have to have your process pretty squared, whether that's seven-day follow-up plus your specific clinical programs. But you also really have to understand at a pretty granular level who that subset of patients is. And we spend a lot of time actually honing in and focusing resources around that small subset to drive a differential outcome. I think Rick's actually a great example of that, someone who has admitted 14 times in the last year, and we brought that down to seven by focusing pretty differentially on his clinical programs. I Think what John talked through as well is just another example of going line by line on a patient level, really working through high-risk, high-utilizing patients and making sure we have tailored treatment plans. As a reminder, if you would like to ask a question or any additional follow-up questions, please raise your hand now. If you have dialed into today's call, please press star nine to raise your hands and star six to unmute. Your next question comes from the line of Thomas Walsh from Barclays. Your line is open, please go ahead. Hi, thanks for sharing so much detail today. I'm sure that patients enrolled in the serious illness care pathway had about a $10,000 reduction in costs from avoidable admissions. Do you have a similar cost reduction metric for the heart failure pathway? And what's the prevalence of heart failure in the Agilent population? Thanks, Thomas. So as far as similar cost reduction number for heart failure, we're still, I would say, early in the pathway. We're seeing those cost outcomes play through. You know, I think the admission metrics that we cited are pretty good literature-based estimates, 20 to 40 percent reduction from baseline for patients who are on guideline-directed medical therapy. I would say it's going to take us a little bit to see that play through in our population, so I don't have an exact cost reduction number for you yet, though I'd say we're optimistic that's going play through. I think you had a second part of your question, if you can just repeat that, Thomas. Sure, just the prevalence of our failure in the population, the Agilon population. Yeah, so I think it's important context to know what national benchmarks are. So national benchmarks, if you combine stage B, C, and D FART failure, are in the 40% to 45% range. If you look at prevalence studies, I would say we are, you know, varies by market, but think of us as in the 30% to 35% range, and again, varies bei geography. Great. That's very helpful. And just a quick follow-up, since a patient's diet is such a key modifiable driver of chronic disease, do you have any current or planned programs focused on dietary intervention? Yeah, it's a good question. And I'm curious, John, I'll let John add some color to, I think diet and nutrition are such a core part of lifestyle medicine and lifestyle interventions that we are talking about with patients every single day. And I know that the advanced wellness visit actually creates, I think, an intentional visit to speak about that with some focus. And so that is how a lot of our physicians are speaking about lifestyle changes that impact chronic disease. And I think from a programmatic perspective, you know, I think, again, we talk about it a lot in the context of chronic diseases that we're managing. It's been talked about from a programmatic perspective, but I don't know that that's going to be the highest priority on our list to take on. But, John, I'll turn it over to you for any additional call around that. Thanks, Karthik. I appreciate the question. And I think one of the things that the Agilon partnership has done for us is to really double down on team-based approach, regardless of the disease state. Heart failure is a great example. Diabetes is another classic example. We've actually hired a dietician in our group and at the network level, in addition to pharmacists, care managers, advanced practice providers, to really provide that team- based approach, which not only includes GDMT, but instructions on appropriate nutrition, physical activity, behavioral health. All of those were clinical capabilities that we could not really provide before. I'll now turn the call over to Megan Kegel to present questions submitted via email. Megan, please go ahead. Thanks, Hillary. Dr. Copeland, I think, is an extension to what you were just saying. I have a question here for you. Can you explain a bit more about the connection you feel to Agilent kind of on a daily basis and how that operates as a physician in a practice? Sure, I'm happy to. We're fortunate here in Detroit and in Michigan, we have among the best teams in the country. One of the things that we joke about is you can't tell who works for whom in terms of the practice. So we've got our Agilon operational folks in the practice daily, weekly, monthly, helping us take better care of our patients. So that kind of connectivity and that kind of proximity isn't just lip service. Those folks are actually incorporated as part of our team as is Karthik, as is Heidi. These are folks that have really helped us transform our practice And if we were designing primary care from scratch, it looks a lot like this. This is the kind of care we would provide. So I'm glad you asked the question because on the ground, in the exam room, in the practice, those folks are well entrenched and meshed in our practice. That's great. Thank you, Dr. Copeland. Varun, I have another question for you. How do you determine which new technology or AI advances you might want to prioritize? And then how do you look externally for solutions to accelerate? That's a great question. So I think predominantly what we've been doing so far is, you know, our proximity with our physicians, as well as, you knows, us being very closer to where care is actually delivered, gives us pretty much a front row seat to look at opportunities where can drive efficiencies right so we've actually been very close to where care is being delivered and that's essentially where we get the signals to figure out where we invest and focus on we've built a fairly you know sophisticated data platform and layers on top of it but at the same time we're also you know very closely engaging with folks in the industry to look at new use cases new tools that come up our product and our technology and our market teams essentially try to match those together and then identify where can we actually drive value for our physicians as well as for our patients. So I think we have signals from our partners. We have a lot of data in terms of where the opportunity is. And number three, we engage very avidly with the industry to essentially look at what's new in the market and see how that matches up to what we want to do. Dr. Rao, another question for you. Can you give us some perspective on the potential value creation for oncology? It seems to be a large cost and continued Part B spend. And then can you compare and contrast that with the more mature heart failure pathway that's already launched? Yeah, happy to, Megan. And so I'll talk a little bit about what we're seeing in oncology. And I think it's important. I think most folks know from a cost driver's perspective, Part B is the fastest growing cost category we have. It's not the biggest, but is the fastest growing, which creates an imperative for us to figure out a solution in that space. We've deep-dived into this in a handful of our markets, and we have specific solutions that we are starting to stand up. We found a few different actionable pieces within oncology. One is utilization of biosimilars, using them appropriately. Two, site of care for drug delivery. Three is making sure our oncology patients are appropriately documented and coded, and we just know not all oncology groups are incentivized to do that properly, and it's really important that those patients actually have the right diagnosis so we can treat those patients appropriately. And four, I'd also say is palliative and hospice care. It is vastly underutilized in the oncology population. And I would say that's oncologists acknowledged as well in many of our markets. And through collaboration and partnership with them, I think we have, I would Say, an obligation for patients to do that. And, I Think, an aligned opportunity with oncology groups to do That as well. And actually, the fifth thing that I would Say that we're finding as well is in these same markets, we're Finding that once a patient has an oncology diagnosis, they actually somewhat lose touch with their PCP, which leads to exacerbations of their disease outside the oncology diagnoses. Think about an oncologist patient that has heart failure. They lose touch to their PCPs. That heart failure is no longer being managed. And so in these markets where we started to test and iterate on oncology solutions, those are the five levers that we're going after. And we're optimistic there's going to be meaningful value in getting that right. It's tough to compare it to heart failure, to your question, Megan, just because we're earlier in the process, and it's true of heart failure as well. We think there's meaningful value, like we did when we started with heart failure. We think it's going to take a little while for us to get to specifics on exactly what that looks like. Thank you, Karthik. The last question is for you. The quality scores, including the 4.2 composite and 3% additional care gap closure are strong results. Can you provide some color on what you think is needed to have such a successful quality program? And then particularly, have there been learnings similar to what Dr. Rao spoke to earlier on the clinical side? Yeah, thanks, Megan. First of all, we're really proud of those results with our physician partners. That is not easy to do as the cut points get higher each year. So reflecting that we're closing more gaps, you know, there's a couple of elements that are required to deliver that strong level of performance. And so the first one is that quality playbook that I talked about. So very consistent programs around chronic condition management, being able to reduce unnecessary admissions, preventive screening, and patient experience. And so required against each of those are a couple of different solutions, end-to-end solutions, that can meet a partner where they are on how to solve for those. That could mean, as an example, I'll use preventive screenings. Some partners have diabetic eye exam cameras in their practice. With others, we work with capabilities to have those cameras taken out even to meet the patient at the home. And so there's different ways to solve those different types of solutions. I think the thing that you continue to see, whether it's in the MA program or through the ACO program with CMS, is that CMS appreciates the value of quality and the impact that frontline PCPs can have on improving that quality. And so key themes that we see across both programs are access to care and the experience. So that's reflected across both of the programs is very meaningful. And then being able to ultimately impact reduction in inpatient stay. And so we've talked a lot about the ability to identify condition earlier, have an end-to-end program and pathway that ultimately has that impact and is able to keep patients out of the hospital, improve their quality of life. You see how that shows up personally to Rick in the story that you heard from him and how that showed up in improving his quality of life. Hopefully, Dr. Copeland brought that to life as he talked about that experience for a frontline PCP. And you heard that from Varun and Dr. Rao and how our tools and programs work together to help to make that experience come to life for each one of our PCPs and and ultimately their patients in our markets to improve quality. Thanks Heidi. And we have one more come through. I'm gonna say Dr. Rao and Dr. Copeland, you can both answer. Do you find that you're able to leverage some more successful physician partners or physician, individual physicians to help other groups achieve a higher level of success? And if so, what does that mean? Yeah, so I'll start at that, John. Maybe I'll turn it over to you. Look, I think there's a spectrum of performance across the network. I think as we talked about earlier, we're reducing that variability gap in performance, and I think we've really seen that over the last couple years, and it's part of what's led to our performance improvement in 26. The other component of that that I would say is really important is how we deploy different interventions and solutions across the network. I think one of the biggest benefits of the network is having many different archetypes of practices to go and test and iterate different solutions around. And what you have to have within that are high-performing partners like United Physicians, like many of our other partners who are willing to go, and experiment, and iterate quickly, and really lean in to even the specialists within their community to go figure out solutions to these tough problems. And what we found when that goes well is it takes probably three to six months to go through this process of solution design iteration to get to a subscale launch, then a deployment across our network. I think that's been a learning for our network as well. You know, two or three years ago, we were maybe scaling things too quickly before we really knew what the value of something was. I would say we've become much more disciplined about that through our network, and I would say our network has leaned into this new process. But John, I'll turn over to you as well for your thoughts. Yeah, thanks, Karthik. I think both within the market, so here in Detroit, we have a pretty complex market, 30,000 senior patients, 140 physicians. We all historically practice in a pretty siloed manner. We were trying to figure out these complicated, difficult problems independently. Now we're able to very quickly and efficiently share best practices with each other. That also applies on the national level. I've learned a lot from our colleagues in Akron, Springfield, Dallas, Pinehurst, North Carolina, to be able to get together with peers who are similar-minded, value-minded and answer the question, how does this model help me take better care of my patients while still providing satisfaction for physicians and their teams, keeps us out of that siloed approach and has really accelerated performance as we start to engage specialists and really expand the scope of our care. And again, frankly, it's keeping a lot of primary care docs practicing longer than they were historically planning on practicing. So really collaborating both within the market and across the country is really a spectacular thing to be a part of. Thank you both. With that, I'll turn the call back to Evan. Thank you, Megan. What you heard today is a repeatable clinical and quality engineered data platform turns insights into action at the point of care. Clinical pathways and quality programs are showing measurable results as you saw today and presented today. As our network grows, our data and insights get stronger. We believe that this will help us deliver better outcomes to patients, durable partnerships with physicians and long-term value for shareholders. A special thank you to Dr. Copeland and United Physicians for sharing their experience and Dr. Rao, Varun, and Heidi. The materials from today are available on our Investor Relations website. Thank you everybody for joining and have a great afternoon. This concludes today's call. Thank you for attending. You may now disconnect.
- Company
- AGILON HEALTH INC
- Keywords
- AGILON HEALTH INC